Comment from Biotechnology Innovation Organization

Summary: The Biotechnology Innovation Organization (BIO) supports the CNPV Pilot Program but urges the FDA to provide greater transparency, regulatory certainty, and clearer guidance regarding eligibility, selection criteria, and review timelines. They specifically advocate for clear definitions of "national priority areas," a focus on maintaining existing review standards, and ensuring the program does not detract from overall FDA review capacity.